Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Revuforj on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Revuforj (revumenib) is a menin inhibitor approved by the FDA for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation, and relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation, in adult and pediatric patients one year of age and older.
Revuforj blocks the interaction between menin and the KMT2A (MLL) protein, disrupting a key signaling pathway that drives leukemic cell growth in patients whose leukemia carries a KMT2A translocation or NPM1 mutation.
Revuforj is intended for patients with relapsed or refractory acute leukemia confirmed to carry a KMT2A translocation, or relapsed or refractory AML with an NPM1 mutation, where no satisfactory alternative treatment exists.
Revuforj is dosed based on body weight and concomitant medicines, typically 270 mg orally twice daily without a strong CYP3A4 inhibitor, or 160 mg orally twice daily with a strong CYP3A4 inhibitor, taken fasted or with a low-fat meal.
Boxed Warning — Revuforj: Differentiation syndrome, which can be fatal, has occurred with Revuforj. QTc interval prolongation and Torsades de Pointes have also occurred in patients receiving Revuforj.
Differentiation syndrome can present with fever, dyspnea, pulmonary infiltrates, and hypotension. It requires immediate corticosteroid therapy and close monitoring; treatment interruption may be needed for severe cases.
Electrolyte abnormalities should be corrected before starting treatment, and ECG monitoring is recommended during therapy. Concomitant use with other QT-prolonging medicines should be approached with caution.
Revuforj may cause fetal harm. Effective contraception should be used during treatment and for four months after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Revuforj is manufactured and marketed by Syndax Pharmaceuticals. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating hematologist-oncologist confirming leukemia diagnosis and KMT2A translocation or NPM1 mutation testing results. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for relapsed or refractory acute leukemia, Revuforj is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Revuforj directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Revuforj should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Revuforj through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hematology-oncology care coordination and documentation for Revuforj access.
Delhi's major hospitals assist patients with prescription support and documentation for Revuforj.
Bangalore's specialist network offers access coordination for eligible leukemia patients seeking Revuforj.
Chennai-based hematology specialists coordinate Revuforj access alongside comprehensive leukemia care.
Hyderabad's care institutions support patients pursuing Revuforj therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Revuforj.
Pune-based specialists assist with prescription support and Revuforj treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Revuforj.
Kochi's specialist units assist patients with the documentation needed for Revuforj access.
Chandigarh's care centers support Revuforj treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Revuforj access process.
Lucknow-based centers assist patients pursuing Revuforj therapy.
Bhubaneswar's institutions support access to Revuforj for eligible patients.
Guwahati's specialists help coordinate Revuforj access for patients across the Northeast.
Patients in other cities across India can also access Revuforj through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
